Digital Health Investment Weekly Report Vol.161: Funding Highlights and Industry Moves

Due to recent changes in the official account push mechanism, we welcome you to set Boom Health as a "starred" account on the official account homepage to get the latest trends and expert insights in the digital healthcare industry第一时间!

01 Global Digital Health Investment and Financing Overview

Artificial Heart Series Product Developer Core Medical Secures Over $100 Million in D-Round Financing

On April 24, Core Medical, a developer of artificial heart series products, secured over $100 million in D-round financing. The round was jointly led by Loyal Valley Capital, the Social Security Fund Zhongguancun Independent Innovation Special Fund, Prosperity7 Ventures (P7) under Aramco Ventures, Cornerstone Capital, and a well-known industry investor. Delian Capital and LinkCap Partners also participated in the investment. The new funding will be used for the incubation of original and disruptive cutting-edge technologies, accelerating innovative product development, and driving the company to continuously lead the global "artificial heart" industry.

Biolinq, a developer of electronic sensors for skin applications, secures $100 million in Series C funding

On April 22, Biolinq, a developer of skin-applied electronic sensors, secured $100 million in Series C funding, led by Alpha Wave Ventures, with participation from existing investors Features Capital, Hikma Ventures, and Taisho Pharmaceutical.

The funds from this round of financing will be used to support Biolinq's regulatory approval process in the United States and enhance its commercial readiness for the launch of its proprietary intradermal glucose sensor.

Health Technology Developer Healthee Secures $50 Million in Series B Funding

On April 22, health tech developer Healthee secured $50 million in Series B funding, led by Key1 Capital, with continued support from Fin Capital, Glilot Capital Partners, and Group11. The funds will be used to expand its product suite, scale up go-to-market operations, and further develop intuitive, AI-driven tools for smarter and more accessible health benefits.

Pulsed Field Catheter Ablation Technology Developer Field Medical Secures $40 Million Series A Financing

On April 22, Field Medical, a developer of pulsed electric field catheter ablation technology, secured $40 million in Series A financing (including $20 million in new capital and $20 million in seed debt converted to equity). The round was led by multiple leading strategic investors, venture capital firms, and family offices, with several seed investors continuing to increase their investments. The funds will be used to advance its next-generation pulsed field ablation (PFA) technology to meet the complex needs of modern cardiac ablation.

Coronary Artery Bypass Technology Researcher AMT Medical Secures $25 Million in Series B Funding

On April 18, AMT Medical, a developer of coronary artery bypass technology, secured $25 million in Series B funding, led by new investors Invest-NL and the European Innovation Council, along with existing investors such as Oost NL. The funds will support further development and regulatory submissions for its Elana cardiac bypass system. The Elana system aims to replace traditional open-chest bypass surgery and is expected to be compatible with surgical robots, enabling robot-assisted minimally invasive procedures.

AI-Driven Clinical and Payer Compliance Platform Brellium Raises $16.7 Million in Series A Funding

On April 17, Brellium, an AI-driven clinical and payer compliance platform, secured $16.7 million in Series A funding led by First Round Capital, Left Lane Capital, and Menlo Ventures, with participation from Digital Health Venture Partners and Necessary Ventures. The funds will be used to drive team growth, product development, and broader applications in healthcare areas such as mental health, weight loss, autism, and end-of-life care.

Peripheral Interventional Device Developer Changde Medical Raises Over RMB 100 Million in A+ Round Financing

On April 23, Changde Medical, a developer of peripheral interventional devices, secured an A+ round of financing exceeding RMB 100 million. The round was led by the Shanghai Biomedical Fund under Shanghai Industrial Capital, with Xingzheng Capital participating as a follower. Existing shareholders Junlian Capital and Huajie High View continued to increase their investments. The funds will primarily be used for pre-market clinical trials and registration applications for the company's innovative products, international registration of core products, and the expansion of domestic and overseas markets.

Innovative Class III Active Implantable Product Developer Core Medical Secures Over RMB 100 Million in Financing

On April 22, Core Medical, an innovative developer of Class III active implantable products, secured over RMB 100 million in financing. The round was jointly led by Longpan Investment and Daotong Investment, with participation from YL Health Fund and Tianrui Fengnian. Existing shareholder Lilly Asia Ventures continued its support, and DSC Capital served as the exclusive financial advisor. The proceeds will primarily be used for the research and development and registration clinical trials of several core products under development.

Kangma Biotech, a developer of reagents and microchips for human health assessment and disease diagnosis, secures hundreds of millions of RMB in financing

On April 23, Biolinq, a developer of human health assessment and disease diagnostic reagents and microchips, secured hundreds of millions of RMB in financing from Binzayed New Energy Technology Investment. Biolinq’s developed Cell-Like System (CLS platform), compared to traditional LNP technology, offers advantages such as low immunogenicity, high stability, and targeting capabilities, enabling the delivery of various nucleic acid drugs.

Endovascular Interventional Surgical Medical Robot R&D Manufacturer Allpon Medical Secures Nearly RMB 100 Million in Series C Financing

On April 21, Allvas Medical, a developer and manufacturer of endovascular interventional surgical robots, secured nearly RMB 100 million in its Series C financing round. The round was jointly led by Jinan International Medical Center Industrial Development Co., Ltd. and Huaiyin District State-owned Capital Holding Co., Ltd. of Jinan City, with participation from Mountain Blue Capital. The funds will be primarily allocated to the research and development, mass production, and commercialization of AI-driven endovascular interventional surgical robots, accelerating the establishment of a globally leading intelligent surgical robot ecosystem.

Junde Medicine, a developer of drug-device combination products and new therapeutic methods, secures nearly RMB 100 million in Series A funding

On April 18, JunDe Pharmaceuticals, a developer of drug-device combination products and new therapeutic methods, secured nearly RMB 100 million in its Series A round of financing. The round was led by Zhangzhou Capital Operation Group and Guoxing Investment, with participation from Pien Tze Huang Investment, Xiamen Hai Venture Capital, and Guoxin Guozheng Investment. Existing shareholder Yingke Capital also followed up with additional investment. The proceeds will primarily be used for the registration, production, and sales of its first weight-loss oral device, as well as to accelerate the R&D progress of multiple core innovative drug-device combination technology platforms.

AI Healthcare Provider Ascertain Secures $10 Million in Series A Funding

On April 22, AI healthcare provider Ascertain secured $10 million in Series A funding, led by Deerfield Management with strategic investment from Northwell Health. The funds will be used to accelerate Ascertain's growth, expand the accessibility of its artificial intelligence solutions, enhance patient care quality, expedite care processes, and enable more efficient care delivery within healthcare systems.

PhotoPharmics, a developer of Parkinson's disease treatment methods, secures $6 million in Series B funding

On April 18, PhotoPharmics, a developer of Parkinson's disease treatments, secured $6 million in Series B funding, led by Kickstart Fund with participation from existing and new investors. The funds will be used to support the Phase III clinical trial of its Parkinson’s phototherapy device, Celeste®, and to finance key pre-commercialization activities to complete FDA studies and prepare for market launch.

Neuroprotective Therapy Developer GenrAb Secures $5.6 Million in Seed Funding

On April 22, neuroprotective therapy developer GenrAb secured $5.6 million in seed funding, led by Actium Group, with participation from Salem Partners, GPG Ventures, Research Bridge Partners, and Maytal Capital. The proceeds will be used to accelerate the development of its lead antibody therapy, TGM-010, and expand its pipeline of neuroprotective drug candidates.

RISA Labs, a medical workflow automation and operation platform, secures $3.5 million in seed funding

On April 17, RISA Labs, a medical workflow automation operations platform, secured $3.5 million in seed funding led by Flipkart co-founder Binny Bansal, with participation from Oncology Ventures, General Catalyst, and others. The funds will be used to accelerate the deployment of RISA Labs' Business Operating System as a Service (BOSS) platform, eliminating prior authorization delays in oncology treatments and enhancing the efficiency and accessibility of cancer care.

Hinge Health Collaborates with Cigna Healthcare to Expand Access to Digital Musculoskeletal Care

April 23,Hinge HealthAnnounced a partnership with Cigna Healthcare aimed at expanding access to digital musculoskeletal (MSK) care solutions for more Americans. Under this arrangement, Cigna Healthcare's self-insured employer clients can now choose to offer their plan members Hinge Health's comprehensive digital MSK platform. This collaboration aims to meet the significant demand for convenient and effective MSK care solutions, helping individuals manage pain and improve function.

Force Therapeutics Partners with ECU Health to Standardize Care and Optimize Patient Engagement

On April 23, surgical care management platform Force Therapeutics announced a strategic partnership with ECU Health of North Carolina. The collaboration aims to automate the collection of Patient-Reported Outcome Measures (PROMs), enhance remote care support, reduce readmission rates, and ensure compliance with CMS requirements. Through this partnership, patient recovery at home will be optimized via intelligent digital care pathways, video-based education, and virtual physical therapy, while streamlining care processes such as virtual joint courses, smart alerts, and customizable watch lists to improve care efficiency and patient engagement.

Private Equity Firm Waud Capital Partners Acquires MedTec Healthcare

On April 21, Altocare, a newly established holding company by private equity firm Waud Capital Partners, acquired MedTec Healthcare, a provider of home care and adult day care services. This acquisition marks a significant step in Waud Capital's strategy to build a leading platform in the home care services market. MedTec will be integrated into Altocare alongside Senior Helpers, creating a comprehensive home care platform focused on serving both self-paying and Medicaid-supported clients.

Musculoskeletal Health R&D Company Zimmer Biomet Acquires Paragon 28

On April 21, musculoskeletal healthcare developer Zimmer Biomet acquired Paragon 28 for $1.2 billion. Paragon 28 is a leading medical device company specializing in the foot and ankle orthopedic sector. Following the acquisition, Paragon 28 became a wholly-owned subsidiary of Zimmer Biomet, with its common stock ceasing trading and delisting from the New York Stock Exchange. This acquisition expands Zimmer Biomet’s foot and ankle product portfolio, leveraging Paragon 28’s expertise and sales channels, and is expected to accelerate Zimmer Biomet’s global growth in the foot and ankle segment while driving its penetration in ambulatory surgery centers (ASCs).

Behavioral Healthcare Company PAX Health Acquires Richardson Psychiatric Associates

On April 17, behavioral health care company PAX Health acquired Richardson Psychiatric Associates, an institution providing comprehensive outpatient mental health services for adults, adolescents, children, and families. This strategic acquisition strengthens PAX Health's mental health service portfolio and expands its geographic coverage in western Pennsylvania, enhancing the company’s ability to deliver high-quality psychiatric care to diverse patient populations.

Healthcare Acquisition and Management Company IHS, LLC Acquires Atlanta Osteoarthritis Center

On April 17, healthcare acquisition and management company IHS, LLC acquired Atlanta Osteoarthritis Center LLC, a top specialty clinic renowned for excellence in regenerative knee care and chronic pain management. This acquisition marks a significant expansion for IHS in the southeastern region and reflects its steadfast commitment to transforming healthcare delivery through innovative, specialized, and compassionate care.

Artery Network/Arterial Orange Industry Think Tank/China Renaissance/BGI Co-Win/Rock Health/Mobile Health News/Fierce Health, etc.

Compiled by: Hou Zhancan, Huang Changjian‍‍‍

Share

Like

Like